www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Share Buy-Back in ALK - release No 10

January 20, 2012

PDF Version

Supporting Materials:
AT_10_UK_20012012.pdf

 

Copenhagen, 2012-01-20 08:30 CET (GLOBE NEWSWIRE) --  

On 15 November 2011, ALK-Abelló A/S ("ALK") initiated a share buy-back programme, cf. company announcement No. 24 of 15 November 2011. According to the programme, ALK will in the period from 15 November 2011 to 30 April 2012 purchase own shares for a maximum amount of DKK 45 million and no more than 150,000 shares corresponding to 1.5% of the current share capital of ALK. The share buy-back programme is initiated and structured in compliance with the EU Commission Regulation No. 2273/2003 of 22 December 2003 and thus ALK will publish the accumulated share buy-back under the programme every week.
 

Trading dayNo of shares
bought back
Average transaction priceAmount (DKK)
43: 13 Jan 2012986327.84323,250
44: 16 Jan 2012223328.0073,144
45: 17 Jan 20121,200331.21397,452
46: 18 Jan 2012300330.5099,150
47: 19 Jan 20121,000333.00333,000
Accumulated for trading days 43-47
3,709

330.55

1,225,996


The accumulated number of shares bought back in the period from 15 November 2011 to 19 January 2012 is 52,973 corresponding to a total purchase sum of DKK 16,797,513. 

As of today, ALK's total holding of own shares is 279,948 shares of a nominal value of DKK 10, corresponding to 2.8% of the total number of issued shares of 10,128,360. 
 

ALK-Abelló A/S
 

Jens Bager
President and CEO
 

For further information please contact:
Per Plotnikof, Investor Relations Director, tel. +45 4574 7527

 

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved